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Abstract
Background: The application of more sensitive imaging techniques, such as ultrasonography (US), changed the
concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to
identify patients developing the erosive phenotype. Anti-citrullinated peptide antibodies (ACPA), associated with
erosions in inflammatory arthritis, have been identified in about 50% of patients with SLE with erosive arthritis.
More recently, anti-carbamylated proteins antibodies (anti-CarP) have been associated with erosive damage in
rheumatoid arthritis. We aimed to assess the association between anti-CarP and erosive damage in a large SLE
cohort with joint involvement.
Methods: We evaluated 152 patients (male/female patients 11/141; median age 46 years, IQR 16; median disease
duration 108 months, IQR 168). All patients underwent blood draw to detect rheumatoid factor (RF) and ACPA
(commercial enzyme-linked immunosorbent assay (ELISA) kit), and anti-CarP (“home-made” ELISA, cutoff 340 aU/
mL). The bone surfaces of the metacarpophalangeal and proximal interphalangeal joints were assessed by US: the
presence of erosions was registered as a dichotomous value (0/1), obtaining a total score (0–20).
Results: The prevalence of anti-CarP was 28.3%, similar to RF (27.6%) and significantly higher than ACPA
(11.2%, p = 0.003). Erosive arthritis was identified in 25.6% of patients: this phenotype was significantly associated with
anti-CarP (p = 0.004). Significant correlation between anti-CarP titer and US erosive score was observed (r = 0.2, p = 0.01).
Conclusions: Significant association was identified between anti-CarP and erosive damage in SLE-related arthritis, in
terms of frequency and severity, suggesting that these antibodies can represent a biomarker of severity in patients with
SLE with joint involvement.
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Background
Joint involvement is one of the most common manifesta-
tions in patients with systemic lupus erythematosus (SLE),
with a prevalence ranging from 69 to 95%. This feature
significantly influences the patients’ quality of life, possibly
leading to disability and impaired functional performance
in daily activities [1]. SLE articular involvement could
range from arthralgia to severe arthropathy, with inflam-
mation and deformities [1–3].
Novel insights suggest that erosive damage, as assessed
by musculoskeletal ultrasonography (US), occurs in up
to 47% of patients with SLE [1, 4–8]. It is likely that such
an erosive phenotype of SLE arthritis may underlie spe-
cific pathogenic mechanisms [1]. Moreover, identifica-
tion of prognostic biomarkers, able to identify patients
at risk of developing this more aggressive phenotype, is
mandatory. Autoantibodies associated with inflamma-
tory arthritis, such as rheumatoid arthritis (RA), have
also been shown to play a role in SLE arthritis. For
instance, anti-citrullinated peptide antibodies (ACPA),
which are associated with a worse outcome and a more
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erosive disease course in RA can be identified in
4.4–27.3% of patients with SLE [9, 10], and their preva-
lence is even higher in patients with x-ray-detected erosive
arthritis, reaching 50% [11, 12].
More recently, anti-carbamylated proteins antibodies
(anti-CarP) have been identified in RA, with a preva-
lence of 16–45% and a significant association with
erosive damage and radiographic progression [13–16].
Carbamylation is a non-enzymatic process consisting
of the addition of a cyanate group on self-proteins
determining a modification in the tertiary structure.
This change can cause the generation of new epi-
topes and the consequent production of autoanti-
bodies [17].
To date, only a few studies have analyzed the preva-
lence of anti-CarP in patients with SLE with joint in-
volvement [18–20]. Thus, in the present cross-sectional
study, we aimed at assessing the association between
anti-CarP and US-detected erosive damage in a large
cohort of patients with SLE with joint involvement.
Methods
In the present cross-sectional analysis, we enrolled con-
secutive patients with SLE with a clinical history of joint
involvement (arthralgia or arthritis), attending the Lupus
Clinic of the Rheumatology Unit, Sapienza University of
Rome (“Sapienza Lupus Cohort”). SLE diagnosis was
performed according to the revised 1997 American
College of Rheumatology criteria [21]. The study was
performed according to the protocol and good clinical
practice principles and Declaration of Helsinki statements
and was approved by the Ethic committee of the Sapienza
University of Rome, Policlinico Umberto I, Rome, Italy.
All the patients gave signed informed consent.
The clinical and laboratory data of enrolled patients
were collected in a standardized computerized electron-
ically filled form, including demographics, past medical
history with the date of diagnosis, co-morbidities and
previous and concomitant treatments. We divided
patients according to the presence of arthralgia or arth-
ritis. Arthralgia was defined as the presence of recurrent
(≥ 3 episodes) or persistent (≥ 6 weeks) pain or stiffness
(lasting at least 30 min of at least one joint) in the
patient’s clinical history. Arthritis was defined as the
occurrence of at least one episode of clinical synovitis
(swelling, effusion or tenderness) and at least 30 min of
morning stiffness of at least one joint.
The activity of joint involvement was assessed with the
swollen-to-tender ratio (STR), previously applied in a
SLE cohort [22]. The SLE Disease Activity Index 2000
(SLEDAI-2 k) was used to assess disease activity, while
chronic damage was evaluated by the Systemic Lupus
International Collaborating Clinics (SLICC) Damage
Index (SDI) [23, 24].
Laboratory evaluation
Each subject underwent peripheral blood sample collec-
tion. The study protocol included the determination of
autoantibodies and the evaluation of C3 and C4 serum
levels. Specifically, anti-nuclear antibodies (ANA) have
been determined by means of indirect immunofluores-
cence (IIF) on HEp-2 (titer ≥ 1:160 or ++, on a scale
from + to ++++), anti-double stranded DNA (anti-dsDNA)
with IIF on Crithidia luciliae (titer ≥ 1:10), extractable nu-
clear antigen (ENA) (including anti-Ro/SSA, anti-La/SSB,
anti-Sm, and anti-RNP) by ELISA, considering titers above
the cutoff of the reference laboratory, anti-cardiolipin
(anti-CL) (IgG/IgM isotype) by ELISA, in serum or plasma,
at medium or high titers (e.g., > 40 GPL or MPL or above
the 99th percentile), anti-β2 glycoprotein-I (anti-β2GPI)
(IgG/IgM isotype) by ELISA, in serum (above the 99th per-
centile), and lupus anticoagulant (LA), according to the
guidelines of the International Society on Thrombosis and
Hemostasis. C3 and C4 serum concentrations were deter-
mined by means of radial immunodiffusion.
Moreover, the presence of rheumatoid factor (RF),
ACPA, and anti-CarP antibodies was investigated. All
autoantibody assays were carried out in triplicate, com-
mercial ELISA kits were used and the results were evalu-
ated according to the manufacturers’ instructions. ACPA
titers were obtained using a commercial ELISA kit
(DELTA BIOLOGICALS, Rome, Italy). Values above
25 U/mL were considered positive. A solid-phase ELISA
kit was used in order to determine RF (Diamedix,
Miami, USA). Diluted samples are incubated with puri-
fied RF antigen (human IgG) bound to the microtiter
well. Any RF-IgM antibody present in the sample binds
to the immobilized human IgG to form antigen-antibody
complexes. Unbound antibody is washed from the wells
and horseradish peroxidase-conjugated anti-human IgM
is added. Values above 10 U/mL were considered
positive. Anti-CarP antibodies were detected by a
“home-made” ELISA, using carbamylated fetal calf
serum (Ca-FCS) and non-modified FCS as antigens.
Ca-FCS was obtained using the method described by Shi
et al. [25]. In brief, Nunc Maxisorp polystyrene plates
(Thermo Scientific, Waltham, MA, USA) were coated
overnight at 4 °C with non-modified FCS and Ca-FCS
(12 μg/ml in 0.05 M Na2CO3/NaHCO3 buffer, pH 9.6).
After washing, plates were blocked with phosphate-buff-
ered saline (PBS), containing 1% bovine serum albumin
(BSA) (Sigma, Saint Louis, Missouri, USA) for 6 h at 4 °C.
Subsequently, the wells were incubated with patients’
serum diluted 1:50 in PBS/0.05% Tween20 (PBS-T)/BSA
1% overnight at 4 °C. Alkaline phosphatase-conjugated
anti-human IgG antibodies (Sigma, Saint Louis, MO,
USA) were diluted in PBS-T/BSA 1% (1:1000), and incu-
bated for 2 h at room temperature. Paranitrophenyl-phos-
phate was used as a substrate and the optical density (OD)
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was measured at 405 nm wavelength. All assays were per-
formed in triplicate and the absorbance of control wells
(non-modified FCS) was subtracted to account for
non-specific binding. A titration curve of two positive
serum samples with medium/high immunoreactivity for
Ca-FCS was performed, to assess the performance of the
tests and to transform the absorbance of Ca-FCS in arbi-
trary units per milliliter (aU/mL). The cutoff was estab-
lished as the mean OD+ 3 standard deviations (SD) of 56
age-matched and sex-matched healthy subjects (blood
donors) and then the obtained value was converted into
arbitrary units per milliliter (corresponding to 340 aU/mL).
Ultrasonographic assessment
US imaging was performed in all patients with SLE using
a MyLab70 XVG machine (Esaote S.p.A., Florence, Italy)
equipped with a 6–18 MHz multifrequency linear array
transducer. By using a fixed 18 MHz frequency, the bone
surfaces of the metacarpophalangeal (MCP) and prox-
imal interphalangeal (PIP) joints were studied on multi-
planar scans according to the European League Against
Rheumatism (EULAR) US guidelines [26]. The first
through the fifth MCP joints of both hands and the first
interphalangeal and the second through the fifth PIP
joints of both hands were evaluated. Each joint was
scanned in both the longitudinal and transverse planes
from the medial to lateral sides on both volar and dorsal
aspects, to enable maximum coverage of the joint sur-
face area. The US examination was obtained independ-
ently on the same day by two rheumatologists (FC and
CP) trained and experienced in musculoskeletal US.
Both sonographers were blinded to the US findings of
the other observer.
At each joint, according to the Outcome Measures in
Rheumatology (OMERACT) definition, the presence of
erosions was registered with a dichotomous value (0/1),
allowing the possibility to obtain a total score, ranging
from 0 to 20 [27]. Moreover, we evaluated the presence
of US inflammatory features (synovial effusion and
hypertrophy, power Doppler), each measured with a
semiquantitative score (0–3), resulting in a total US in-
flammatory score (0–180).
Statistical analysis
The statistical analyses were performed using version 5.0
of the GraphPad statistical package. Normally distributed
variables were summarized using the mean ± standard de-
viation (SD), and non-normally distributed variables by
the median and interquartile range (IQR). Frequencies
were expressed by percentage. Wilcoxon’s matched pairs
test and the paired t test were performed accordingly.
Univariate comparisons between nominal variables were
calculated using the chi-square test or Fisher’s exact test,
where appropriate. Kruskal-Wallis one-way analysis of
variance was applied to evaluate the comparisons between
multiple groups. Spearman’s test was used to test correl-
ation. Two-tailed P values were reported; P values less
than 0.05 were considered significant.
Multivariate analysis was performed using binary logis-
tic regression. The results are presented as standard
error (SE) with the 95% confidence interval (CI). In
order to perform the multivariate analysis, we used a
step-forward model including, progressively, those
variables with P < 0.1 (to also include those with a trend to-
ward an association) to have a stronger model. Area under
the receiver operating characteristic curve (ROC-AUC)
was analyzed to evaluate the sensitivity and specificity of
anti-CarP and ACPA in identifying the presence of erosive
arthritis. Interobserver reproducibility was determined
using κ statistics, and κ values were evaluated according to
the method of Landis and Koch [28].
Results
We evaluated 152 patients with SLE with joint involve-
ment (male/female patients 11/141; median age 46 years,
IQR 16; median disease duration 108 months, IQR 168).
Demographic, clinical and immunological features of en-
rolled patients, according to disease course, are reported
in Table 1.
Skin involvement represented the most frequent
SLE-related manifestation identified in 75.8% of patients,
and more than 90% of patients were treated by glucocorti-
coids and hydroxychloroquine. During the disease course,
47 patients (30.9%) had arthralgia. The remaining 105
patients experienced at least one episode of arthritis, and
Jaccoud’s arthropathy was described in 17 patients
(16.2%). The mean ± SD interval between the arthritis on-
set and the blood sample collection was 14.5 ± 10.3 years.
At the time of the enrollment, the median SLEDAI-2 k
was 2 (range 0–10, IQR 4). Concerning the joint
involvement activity, the entire population had a STR
(mean ± SD) = 0.34 ± 0.5 (median 0.05, IQR 0.7).
Figure 1a shows the prevalence of anti-CarP, RF and
ACPA in the study cohort.
Anti-CarP-positive (n = 42, 28.3%) and RF-positive
(n = 42, 27.6%) patients were significantly more prevalent
than ACPA-positive patients (n = 17, 11.2%; P = 0.003).
The median anti-CarP titer was 185.5 UA/ml (IQR 333.9),
the median ACPA was 0 UI/ml (IQR 3.42) and the median
RF was 7 (IQR 20.7). In Fig. 1b data are reported on the
frequency of anti-CarP, RF and ACPA according to joint
involvement phenotype. The prevalence of anti-CarP and
RF was similar in patients with SLE with arthritis and
arthralgia (anti-CarP, 31 patients with arthritis (29.5%)
versus 11 patients (23.4%) with arthralgia, P value not sig-
nificant; RF, 31 patients with arthritis (29.5%) versus 12
patients with arthralgia (25.5%), P value not significant).
Conversely, ACPA were significantly more frequent in
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patients with arthritis (16 patients, 15.2%) in compari-
son with those experiencing arthralgia (1 patient,
2.1%; P = 0.01).
Figure 2 reports the number and the percentage of
single-positive, double-positive and triple-positive patients
with SLE: 73 patients (48.0%%) were negative for all auto-
antibodies. Of note, anti-CarP antibodies were identified
in 24.5% of ACPA-negative and RF-negative patients.
Anti-CarP-positive patients had significantly higher
prevalence of ACPA, compared to anti-CarP-negative
patients (23.2% versus 6.4%, P = 0.001).
Anti-CarP titers were significantly correlated with
C-reactive protein (CRP) values (r = 0.3, P = 0.02) and STR
values (r = 0.3, P = 0.02). Moreover, also ACPA titers were
significantly correlated with STR values (r = 0.1, P = 0.003).
Interobserver agreement was statistically significant
when bone erosions were evaluated (P < 0.0001). A com-
parison of the results from the two sonographers showed
that the overall unweighted κ value for the examined
joints was 0.72 (agreement in 87.5% of examinations).
US evaluation of the enrolled patients with SLE
allowed the identification of erosive arthritis in 39 pa-
tients with SLE (25.6%), with a mean ± SD erosive score
of 2.9 ± 2.7 (median 2, IQR 3). All the patients with ero-
sive damage reported at least one episode of clinically
evident synovitis during the disease course. The preva-
lence of erosive damage was significantly higher in
anti-CarP-positive compared with anti-CarP-negative pa-
tients (43.6% versus 22.1%, P = 0.004, Fig. 3). Moreover,
ACPA-positive patients had significantly higher preva-
lence of erosive damage than ACPA-negative patients
(25.6% versus 6.2%, P = 0.0008), while a similar prevalence
was observed in RF-positive vs RF-negative patients with
SLE(25.6% versus 29.3%, P value not significant).
When considering the subgroup of anti-CarP single-
positive patients, erosive damage was identified in 25% of
patients. Interestingly, anti-CarP titers were significantly
correlated with the US erosive score (r = 0.21, P = 0.01;
Table 1 Demographic features, clinical and laboratory
manifestations and treatments in152 patients with SLE
Value
Clinical manifestations – N (%)
Skin involvement 115 (75.7)
Serositis 31 (20.4)
Hematological manifestations 99 (65.1)
Neuropsychiatric involvement 15 (9.9)
Renal involvement 33 (21.7)
Laboratory manifestations – N (%)
Anti-dsDNA 114 (78.9)
Anti-Sm 28 (18.4)
Anti-SSA 62 (40.8)
Anti-SSB 35 (23.0)
Anti-RNP 24 (15.8)
Anti-cardiolipin IgG/IgM 44 (28.9)
Anti-β2GPI IgG/IgM 38 (25.0)
Lupus anticoagulant 39 (25.6)
Low C3/C4 levels 81 (53.3)
Treatments – N (%)
Glucocorticoids 140 (92.1)
Hydroxychloroquine 144 (94.7)
Cyclosporine A 34 (22.4)
Methotrexate 59 (38.8)
Cyclophosphamide 6 (3.9)
Mycophenolate mofetil 43 (28.3)
Azathioprine 29 (19.1)
Rituximab 4 (2.6)
Belimumab 9 (5.9)
SLE systemic lupus erythematosus
Fig. 1 a Prevalence of anti-carbamylated proteins antibodies (anti-CarP), rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in
the enrolled patients with systemic lupus erythematosus (SLE) (N = 152). b Prevalence of anti-CarP, RF and ACPA according to the phenotype of
joint involvement (arthritis/arthralgia). NS, not significant
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Fig. 4a); conversely, there was no association between
erosive score and ACPA or RF titers. The median US total
inflammatory score was 4 (IQR 14). There was significant
correlation between this score and anti-CarP titer (r = 0.4,
P < 0.001; Fig. 4b).
According to the positivity cutoff for anti-CarP to dis-
tinguish between patients with and without erosive arth-
ritis (Fig. 5). For anti-CarP, with a cutoff of 354.4 aU/mL
the AUC was 0.66 (SE 0.05, sensitivity 43.6%, specificity
79.8%, likelihood ratio 2.16; Fig. 5a). For ACPA, we the
AUC was 0.59 (SE 0.05, sensitivity 25.6%, specificity
92.6%, likelihood ratio 3.46; Fig. 5b) for a cutoff value of
23.2 UI/mL. The multivariate analysis confirmed the
association between erosive arthritis and anti-CarP
(P = 0.04, SE 0.49, 95% CI 1.0–6.9) and Jaccoud ar-
thropathy (P = 0.01, SE 0.6, 95% CI 1.4–15.5).
Discussion
The present study is the first specifically designed to
evaluate the role of anti-CarP as a biomarker of erosive
damage in patients with SLE joint involvement. By evalu-
ating a large single-center cohort, we identified a signifi-
cant association between anti-CarP and erosive damage.
Interestingly, our results suggest that anti-CarP may prove
useful as a biomarker of activity, as demonstrated by cor-
relation with the US inflammatory score, CRP and STR.
Despite the relatively high frequency of joint involve-
ment in patients with SLE, the pathogenetic picture re-
mains incomplete and specific biomarkers are lacking
[1]. Several studies suggest that a predisposing genetic
background is detrimental in the development of joint
involvement [29–31]. For instance, Ciccacci et al. ob-
served an association between joint involvement and
mir146a rs2910164 gene variant [32]. These genetic
modifications could contribute to T cell activation
through the interaction with antigen presenting cells via
T cell receptor and co-stimulatory molecules. This acti-
vation finally leads to B cell proliferation and production
of autoantibodies [1]. Similar to RA, proteins deriving
from post-translational modifications, such as citrullina-
tion or carbamylation, could activate this process [1, 17].
The role of ACPA as biomarkers of a more aggressive
disease phenotype has been widely investigated both in
RA and SLE. Indeed, these autoantibodies can be fre-
quently found in patients with SLE with x-ray-detected
erosive arthritis [11]. Nonetheless, most patients with
SLE with erosive arthritis are ACPA-negative, suggesting
a different pathogenic scenario [12].
Carbamylation occurs in several inflammatory condi-
tions including RA and psoriatic arthritis [33]. In RA,
anti-CarP antibodies have been identified in 16% of sero-
negative (ACPA and RF negative) patients and seem to
correlate with bone erosions and radiographic progres-
sion. Anti-CarP have also been evaluated in patients af-
fected with SLE. Specifically, Ziegelasch et al. identified
association between anti-CarP and radiographically de-
tected erosions in a small cohort of patients with SLE
[19]. We previously identified anti-CarP in 46.1% of pa-
tients with SLE with joint involvement, a prevalence
matching that in patients with RA and significantly
higher than that in healthy controls (2.4%). We also
found that anti-CarP-positive patients were significantly
more frequent than ACPA-positive patients [20].
With the present study, we add a piece to the puzzle
suggesting that anti-CarP may be involved in the develop-
ment of erosive damage in SLE, since anti-CarP-positive
patients are more prevalent among those with
US-detected erosions and anti-CarP titers correlate with
Fig. 2 Distribution of single-positive, double-positive and triple-positive
patients with systemic lupus erythematosus. RF, rheumatoid factor;
ACPA, anti-citrullinated protein antibodies; aCarP, anti-carbamylated
protein antibodies
Fig. 3 Prevalence of erosive damage according to the autoantibody
status. aCarP, anti-carbamylated protein antibodies; ACPA,
anti-citrullinated protein antibodies; RF, rheumatoid factor; NS,
not significant
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US erosive score. This result was confirmed in the
multivariate analysis. Moreover, the ROC curve ana-
lysis demonstrated high specificity of anti-CarP to dif-
ferentiate between patients with and without erosive
arthritis.
The pathogenetic mechanism leading to erosive
damage has been investigated, especially in RA. In
this context autoantibodies, including ACPA and
anti-CarP, seem to play a pathogenetic role by acting
on bone-resorbing osteoclasts. ACPA have been
shown to bind to osteoclasts and osteoclast precur-
sors, promoting osteoclast differentiation and osteo-
lytic function in vitro [34]. Moreover, binding of
ACPA to osteoclast precursors could promote the re-
lease of pro-inflammatory and pro-osteoclastogenic
cytokines, such as TNF, linking autoimmunity and
inflammation [34]. We could hypothesize that such a
mechanism occurs in anti-CarP-positive patients with SLE.
This scenario seems to be confirmed by the correlation
between anti-CarP titers and inflammatory parameters, such
as US inflammatory score, CRP and STR, as observed in
our cohort.
Paralleling ACPA behavior, anti-CarP could induce
the production of pro-inflammatory cytokines, lead-
ing to a more active phenotype. Nonetheless,
anti-CarP seem specifically involved in joint involve-
ment development rather than being markers of dis-
ease activity, since they do not correlate with disease
activity indices, such as the SLEDAI-2 k. We may
hypothesize that NETosis-derived myeloperoxidase
could locally determine a pro-carbamylation milieu,
leading to the break of immune tolerance and to the
production of antibodies directed against carbamy-
lated proteins [20]. NETosis, the specific neutrophil
death, plays a fundamental role in SLE pathogenesis:
several data have shown increased NETosis in pa-
tients with SLE, which significantly correlated with
disease activity [35].
Finally, we have chosen to use US assessment, given
its high sensitivity in the detection of bone erosions and
soft-tissue lesions. Indeed, US is more sensitive than
x-ray in detecting bone erosions at the MCP and meta-
tarsophalangeal joints in patients affected by RA, com-
pared to magnetic resonance imaging and computed
Fig. 4 Correlation between anti-carbamylated protein antibodies (anti-CarP) titers and ultrasound (US) erosive (a) and inflammatory score (b). STR,
swollen-to-tender ratio
Fig. 5 ROC curve analysis for anti-carbamylated protein antibodies (anti-CarP) (a) and anti-citrullinated protein antibodies (ACPA) (b)
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tomography, especially during the early disease phase
[36, 37].
Conclusions
The results of the present study suggest that anti-CarP
could be considered as a candidate biomarker of severity
and activity in SLE joint involvement. Further studies
are needed to confirm this issue and to identify the
pathogenetic mechanism underlining this association.
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